Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin

LAUSEKER, Michael, Katharina BACHL, Anna TURKINA, Edgar FABER, Witold PREJZNER, Ulla OLSSON-STROMBERG,, Michele BACCARANI, Elza LOMAIA, Daniela ŽÁČKOVÁ, Gert OSSENKOPPELE, Laimonas GRISKEVICIUS, Gabriele SCHUBERT-FRITSCHLE, Tomasz SACHA, Sonja HEIBL, Perttu KOSKENVESA, Andrija BOGDANOVIC, Richard E. CLARK, Joelle GUILHOT, Verena S. HOFFMANN, Joerg HASFORD, Andreas HOCHHAUS a Markus PFIRRMANN. Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin. American Journal of Hematology. Hoboken: John Wiley & Sons, roč. 94, č. 11, s. 1236-1243. ISSN 0361-8609. doi:10.1002/ajh.25628. 2019.

Základní údaje

• Originální název: Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin
• Autoři: LAUSEKER, Michael (276 Německo, garant), Katharina BACHL (276 Německo), Anna TURKINA (643 Rusko), Edgar FABER (203 Česká republika), Witold PREJZNER (616 Polsko), Ulla OLSSON-STROMBERG, (752 Švédsko), Michele BACCARANI (380 Itálie), Elza LOMAIA (643 Rusko), Daniela ŽÁČKOVÁ (203 Česká republika, domácí), Gert OSSENKOPPELE (528 Nizozemské království), Laimonas GRISKEVICIUS (440 Litva), Gabriele SCHUBERT-FRITSCHLE (276 Německo), Tomasz SACHA (616 Polsko), Sonja HEIBL (40 Rakousko), Perttu KOSKENVESA (246 Finsko), Andrija BOGDANOVIC (688 Srbsko), Richard E. CLARK (826 Velká Británie a Severní Irsko), Joelle GUILHOT (250 Francie), Verena S. HOFFMANN (276 Německo), Joerg HASFORD (276 Německo), Andreas HOCHHAUS (276 Německo) a Markus PFIRRMANN (276 Německo).
• Vydání: American Journal of Hematology, Hoboken, John Wiley & Sons, 2019, 0361-8609.

Další údaje

• Originální jazyk: angličtina
• Typ výsledku: Článek v odborném periodiku
• Obor: 30205 Hematology
• Stát vydavatele: Spojené státy
• Utajení: není předmětem státního či obchodního tajemství
• WWW: URL
• Impakt faktor: Impact factor: 6.973
• Kód RIV: RIV/00216224:14110/19:00112499
• Organizační jednotka: Lékařská fakulta
• Doi: http://dx.doi.org/10.1002/ajh.25628
• UT WoS: 000490182700018
• Klíčová slova anglicky: WORLD-HEALTH-ORGANIZATION; CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE INHIBITORS; 2904 CML PATIENTS; RANDOMIZED CML; SURVIVAL; MANAGEMENT; IMATINIB; ERA; RECOMMENDATIONS
• Štítky: 14110212, rivok
• Příznaky: Mezinárodní význam, Recenzováno

Anotace

Chronic myeloid leukemia (CML) is usually diagnosed in chronic phase, yet there is a small percentage of patients that is diagnosed in accelerated phase or blast crisis. Due to this rarity, little is known about the prognosis of these patients. Our aim was to identify prognostic factors for this cohort. We identified 283 patients in the EUTOS population-based and out-study registries that were diagnosed in advanced phase. Nearly all patients were treated with tyrosine kinase inhibitors. Median survival in this heterogeneous cohort was 8.2 years. When comparing patients with more than 30% blasts to those with 20-29% blasts, the hazard ratio (HR) was 1.32 (95%-confidence interval (CI): [0.7-2.6]). Patients with 20-29% blasts had a significantly higher risk than patients with less than 20% blasts (HR: 2.24, 95%-CI: [1.2-4.0], P = .008). We found that the blast count was the most important prognostic factor; however, age, hemoglobin, basophils and other chromosomal aberrations should be considered as well. The ELTS score was able to define two groups (high risk vs non-high risk) with an HR of 3.01 (95%-CI: [1.81-5.00], P < .001). Regarding the contrasting definitions of blast crisis, our data clearly supported the 20% cut-off over the 30% cut-off in this cohort. Based on our results, we conclude that a one-phase rather than a two-phase categorization of de novo advanced phase CML patients is appropriate.